Open AccessDoubling Down on Mutant RAS Can MEK or Break Leukemia
Author(s) -
Zuzana Tóthová,
Benjamin L. Ebert
Publication year - 2017
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2017.02.013
Subject(s) - biology , mutant , leukemia , microbiology and biotechnology , genetics , cancer research , gene
Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of Kras G12D mutant acute myeloid leukemia and propose its use as a predictive biomarker.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom